CTOs on the Move

Medac Corporation

www.medac.com

 
Medac Corporation is a Augusta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.medac.com
  • 804 Scott Nixon Memorial Dr
    Augusta, GA USA 30907
  • Phone: 706.650.0705

Executives

Name Title Contact Details
Sam Bruce
Chief Information Security Officer Profile

Similar Companies

Monte Rosa Therapeutics

Small molecule protein degraders are set to reshape the way by which diseases will be treated. Our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. Headquartered in Boston with additional laboratory facilities in Basel, Monte Rosa Therapeutics is a private company launched in 2020. Initially seeded by Versant Ventures and incubated at Ridgeline Discovery in Basel, and The Institute of Cancer Research in London, Monte Rosa has raised $32.5 million from Versant and New Enterprise Associates. Academic co-founders are Prof. Raj Chopra and Prof. Ian Collins of The Institute for Cancer Research, UK.

Angstrom Pharmaceuticals

Angstrom Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Javan and Walter

Javan and Walter, Inc is a Glen Burnie, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Warner Chilcott

Warner Chilcott is a Rockaway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Erytech

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH`s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company`s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell`s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.